Values First Advisors, Inc. Neurocrine Biosciences Inc Transaction History

Values First Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $54,489 - $71,228	579 New	579 $58,000
Q2 2021 Nov 15, 2022	SELL	$89.43 - $102.27 $217,583 - $248,822	-2,433 Closed	0 $0
Q1 2021 Nov 15, 2022	BUY	$87.57 - $119.4 $213,057 - $290,500	2,433 New	2,433 $237,000
Q4 2020 Nov 15, 2022	BUY	$86.91 - $108.33 $209,713 - $261,400	2,413 New	2,413 $231,000
Q3 2020 Nov 15, 2022	SELL	$96.16 - $135.15 $180,876 - $254,217	-1,881 Closed	0 $0
Q2 2020 Nov 15, 2022	SELL	$85.09 - $130.36 $6,041 - $9,255	-71 Reduced 3.64%	1,881 $230,000
Q4 2019 Nov 15, 2022	BUY	$86.8 - $118.57 $169,433 - $231,448	1,952 New	1,952 $210,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.